Articles related to ATRIAL FIBRILLATION (AFIB)

The study’s findings call for risk stratification and follow-up in patients with transient new-onset AF during hospitalization.

This study offers valuable insights into the comparative efficacy and safety of apixaban and rivaroxaban in obese patients with NVAF, highlighting the need for a patient-centered approach in anticoagulant selection.

Marlex Pharmaceuticals has initiated a critical recall of specific lots of Digoxin Tablets due to a labeling error. Physicians are urged to exercise extreme caution and verify their inventory to prevent adverse patient outcomes.

The SAGE-AF study provides valuable insights into the cost-reducing behaviors among older adults with atrial fibrillation, highlighting the need for targeted interventions, especially for those with cognitive impairments. Explore the study to understand how these behaviors are shaping medication management in this vulnerable population.

Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.

Navigating the Interplay of Eliquis and Dietary Habits As physicians, understanding the nuances of apixaban (Eliquis) and its interaction with diet is crucial for optimal patient care. While taking Eliquis, there are no specific foods to avoid, but people with cardiovascular issues should steer clear of coffee and foods heavy in fat.